HEALTH ALERT! If you have any of the following, please call our office before coming in for your appointment: Fever AND cough; Fever OR cough and recent travel (domestic or international to any destination); Recent international travel to areas impacted by the Coronavirus (2019-nCoV) within the last 14 days; OR close contact with someone who has traveled outside the US or been exposed to the Coronavirus. Read more

Treatments & Services

Available Trials



Bladder


Breast


Cholangiocarcinoma


Colorectal


Endometrial


Gynecological/Ovarian


Hematology

  • USOR 18130/INCB 39110-309 Ph3 Itacitinib GVHD (GRAVITAS309)

    USOR 18130 INCB 39110-309: A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309.)

    Available at Niles, Arlington Heights

  • USOR 08160/M07-001 PNH Registry

    USOR 08160 PNH Registry: Primary Objective of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry will Collect Data to Evaluate Safety Data Specific to the Use of Solaris and to Characterize the Progression of PNH as well as Clinical Outcomes, Mortality and Morbidity in Solaris and Non-Solaris Treated Patients. Secondary Objective is Raising PNH Awareness in the Medical Community and Patient/Potential Patient Population. (M07-001)

    Available at Niles, Arlington Heights


Leukemia


Lung - Non-Small Cell Lung

  • USOR 20137 GO41854 PH3 Atez Tira Dura Sg 3 NSCLC

    NOW OPEN USOR 20137: A Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab Compared with Durvalumab in Patients with Locally Advanced, Unresectable, Stage III, Non-Small Cell Lung Cancer, Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation (SKYSCRAPER-03) (GO41854)

    Available at Arlington Heights, Niles

  • USOR 19018 516-005 Mirati Ph 3 Sit + Nivo vs Docetaxel NSCLC

    USOR 19018: A Randomized, Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE) Mirati 516-005

    Available at Arlington Heights, Niles

  • USOR 19192 Ph3 Tira atezo NSCL GO41717

    USOR 19192 A Phase III, Randomized, Double-Blinded, Placebo-Controlled Study of Tiragolumab, An Anti-Tigit Antibody, In Combination with Atezolizumab, Compared with Placebo In Combination With Atezolizumab, In Patients With Previously Untreated, Locally Advanced, Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer. (GO41717)

    Available at Arlington Heights, Niles

  • USOR 19044 / D9103C00001 Pacific-4/RTOG-3515 NSCLC

    USOR 19044: A Phase III, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with Unresected Stage I/II, Lymph-Node Negative Non-Small Cell Lung Cancer. (D9103C00001)(PACIFIC-4/RTOG-3515)

    Available at Niles


Lymphoma


Multiple Myeloma


Myelomas

  • USOR 18230 207503 Ph3 R/R MM (DREAMM 7)

    USOR 18230 DREAMM 7: A Multicenter, Open- Label, Randomized, Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared with the Combination of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) in Participants with Relapsed/Refractory Multiple Myeloma (207503.)

    Available at Arlington Heights, Niles


Pancreas


PNH

  • USOR 08160/M07-001 PNH Registry

    USOR 08160 PNH Registry: Primary Objective of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry will Collect Data to Evaluate Safety Data Specific to the Use of Solaris and to Characterize the Progression of PNH as well as Clinical Outcomes, Mortality and Morbidity in Solaris and Non-Solaris Treated Patients. Secondary Objective is Raising PNH Awareness in the Medical Community and Patient/Potential Patient Population. (M07-001)

    Available at Niles, Arlington Heights


Prostate


Solid Tumor